Potential Weak Interaction
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration has not been studied. In vitro data suggest that pyrimethamine inhibits the renal transporters OCT2 and MATE1. Coadministration could potentially decrease emtricitabine renal elimination (via inhibition of MATE1), but no effect on tenofovir renal elimination is expected as tenofovir is primarily excreted via OAT1 and MRP4. No a priori dosage adjustment is recommended in patients with normal renal function.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking